Primary analysis of ZUMA7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus StandardofCare (SOC) therapy in patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) Meeting Abstract
| Authors: | Ghobadi, A.; Locke, F. L.; Miklos, D. B.; Jacobson, C. A.; Perales, M. A.; Kersten, M. J.; Oluwole, O. O.; Rapoport, A. P.; McGuirk, J. P.; Pagel, J. M.; Muñoz, J.; Farooq, U.; van Meerten, T.; Reagan, P. M.; Sureda, A.; Flinn, I. W.; Vandenberghe, P.; Song, K. W.; Dickinson, M.; Minnema, M. C.; Riedell, P. A.; Leslie, L. A.; Chaganti, S.; Yang, Y.; Filosto, S.; Schupp, M.; To, C.; Cheng, P.; Gordon, L. I.; Westin, J. R. |
| Abstract Title: | Primary analysis of ZUMA7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus StandardofCare (SOC) therapy in patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) |
| Meeting Title: | 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) |
| Journal Title: | Molecular Therapy |
| Volume: | 30 |
| Issue: | 4 Suppl. 1 |
| Meeting Dates: | 2022 May 16-19 |
| Meeting Location: | Washington, DC |
| ISSN: | 1525-0016 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2022-05-02 |
| Start Page: | 519 |
| Language: | English |
| ACCESSION: | WOS:000794043702284 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ymthe.2022.04.017 |
| Notes: | Meeting Abstract: 1113 -- Source: Wos |
